|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C11orf95 |
Gene summary for C11ORF95 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C11orf95 | Gene ID | 65998 |
| Gene name | zinc finger translocation associated | |
| Gene Alias | C11orf95 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | C9JLR9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65998 | C11orf95 | HCC1_Meng | Human | Liver | HCC | 5.77e-22 | 1.15e-02 | 0.0246 |
| 65998 | C11orf95 | HCC1 | Human | Liver | HCC | 2.37e-05 | 3.05e+00 | 0.5336 |
| 65998 | C11orf95 | HCC2 | Human | Liver | HCC | 4.66e-05 | 2.50e+00 | 0.5341 |
| 65998 | C11orf95 | S014 | Human | Liver | HCC | 5.78e-13 | 5.75e-01 | 0.2254 |
| 65998 | C11orf95 | S015 | Human | Liver | HCC | 2.21e-07 | 3.91e-01 | 0.2375 |
| 65998 | C11orf95 | S016 | Human | Liver | HCC | 8.84e-14 | 5.00e-01 | 0.2243 |
| 65998 | C11orf95 | S028 | Human | Liver | HCC | 6.54e-04 | 2.76e-01 | 0.2503 |
| 65998 | C11orf95 | S029 | Human | Liver | HCC | 4.46e-03 | 2.65e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C11orf95 | SNV | Missense_Mutation | novel | c.244G>T | p.Asp82Tyr | p.D82Y | C9JLR9 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AC-A3YJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| C11orf95 | deletion | Frame_Shift_Del | novel | c.840delN | p.Asn281ThrfsTer70 | p.N281Tfs*70 | C9JLR9 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| C11orf95 | SNV | Missense_Mutation | novel | c.305G>A | p.Arg102Gln | p.R102Q | C9JLR9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C11orf95 | SNV | Missense_Mutation | novel | c.308G>A | p.Arg103His | p.R103H | C9JLR9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| C11orf95 | SNV | Missense_Mutation | novel | c.460N>A | p.His154Asn | p.H154N | C9JLR9 | protein_coding | tolerated(0.33) | benign(0.067) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C11orf95 | SNV | Missense_Mutation | novel | c.305N>A | p.Arg102Gln | p.R102Q | C9JLR9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| C11orf95 | SNV | Missense_Mutation | novel | c.465G>T | p.Trp155Cys | p.W155C | C9JLR9 | protein_coding | deleterious(0) | possibly_damaging(0.609) | TCGA-BS-A0U8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| C11orf95 | SNV | Missense_Mutation | novel | c.284G>A | p.Arg95His | p.R95H | C9JLR9 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C11orf95 | insertion | Frame_Shift_Ins | novel | c.193_194insC | p.Leu65ProfsTer21 | p.L65Pfs*21 | C9JLR9 | protein_coding | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| C11orf95 | SNV | Missense_Mutation | novel | c.353N>G | p.Asn118Ser | p.N118S | C9JLR9 | protein_coding | deleterious(0.02) | benign(0.099) | TCGA-CC-A8HV-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |